AKYNZEO injection, an IV solution, was designed to prevent acute and delayed CINV and help support operational efficiency1
|AKYNZEO Injection1-3||Cinvanti® injectable emulsion4||Fosaprepitant for injection5|
|Inhibits NK-1 pathway||✓||✓||✓|
|Inhibits 5-HT3 pathway||✓||No||No|
|Includes palonosetron (strong binding affinity and 58-hour half life)||✓||No||No|
|NK-1 half-life >120 hours in cancer patients||✓||N/A*||N/A*|
|Compatible with IV dexamethasone; can be added to solution or infused simultaneously||✓||No||No|
|Does not require 30-minute delay after administration||✓||No||No|
|Does not require refrigeration at any point during distribution, storage, or preparation||✓||No||No|
*Data not available in cancer patients. Half-life of CINVANTI and fosaprepitant in healthy subjects was 9 to 13 hours.
Pharmacological data cannot be used to make clinical comparisons of efficacy between treatments.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) include netupitant/fosnetupitant and palonosetron fixed combination (AKYNZEO) as a Category 1 recommended option for parenteral MEC and HEC regimens2
- 5-HT3 RA=5-HT3 receptor antagonist; CINV=chemotherapy-induced nausea and vomiting; HEC=highly emetogenic chemotherapy; MEC=moderately emetogenic chemotherapy; NK-1 RA=neurokinin-1 receptor antagonist.
Cinvanti is a registered trademark of Heron Therapeutics, Inc.
AKYNZEO Limitations of Use
AKYNZEO for injection and AKYNZEO injection have not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.